Stocks › Biotechnology › ACRS

Aclaris Therapeutics ACRS

US equityMarket cap rank #3745Biotechnology

$3.40 −$0.30 (-8.11%)

Pre-market · Oct 8, 9:10 am ET · After hours $3.46 +1.76%

Open$3.60

Prev close$3.70

Day range$3.32 – $3.62

Volume9.00M

Market cap$500.48M

P/E (TTM)–

Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership84.1%-1.63 pts vs. prior quarter

Institutions holding173+0 vs. prior quarter

Insider trades (recent)40 buys / 10 sellsNet buying

Short interest10.92% of floatDays to cover 6.4 · as of 15 Sep 2026

Short-sale volume share15.4%5-day average of daily volume

Short-sale volume as % of daily volume

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: +$4.42M (6 inflow days, 14 outflow days).

Net flow by order size, last 20 sessions

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 35.9% of shares outstanding.

Largest holders

RA Capital Management, L.P.8.64%
BML Capital Management, LLC8.14%
BlackRock6.82%
Deep Track Capital, LP6.35%
Frazier Life Sciences Management, LP5.93%
Vanguard Capital Management, LLC4.57%
Vivo Capital, LLC4.55%
Rock Springs Capital Management LP2.94%

By investor type

VC/PE Fund31.22%
Mutual Fund26.64%
Hedge Fund24.78%
Individual/Insider2.21%
Public Company0.78%
Private Company0.40%
Insurance Company0.17%
Government Pension Fund0.10%

Reported short interest has risen from 8.17% to 10.92% of float over the last 6 biweekly reports (30 Jun 2026 to 15 Sep 2026).

Recent institutional activity

Holder	Type	Period	Share change	New stake
Frazier Life Sciences Management, LP	VC/PE Fund	2026/Q3	+3,804,142	5.9%
Nuveen Asset Management LLC	Insurance Company	2026/Q3	+249,775	0.2%
RA Capital Management, L.P.	VC/PE Fund	2026/Q3	+5,918,954	8.6%
BlackRock	Mutual Fund	2026/Q3	+2,629,943	6.8%
Silverarc Capital Management, LLC	Hedge Fund	2026/Q3	+1,946,482	1.3%
Jones Hill Capital LP	Hedge Fund	2026/Q3	+1,759,492	1.2%
State Street Global Advisors	Mutual Fund	2026/Q3	+1,246,594	2.2%
Vanguard Capital Management, LLC	Mutual Fund	2026/Q3	+928,711	4.6%
PanAgora Asset Management, Inc.	Mutual Fund	2026/Q3	+853,862	0.9%
Geode Capital Management, LLC	Mutual Fund	2026/Q3	+766,367	2.2%
MPM BioImpact LLC	VC/PE Fund	2026/Q3	+650,549	0.7%
Braidwell LP	Hedge Fund	2026/Q3	+443,232	1.5%
OrbiMed Advisors LLC	VC/PE Fund	2026/Q3	+421,500	0.3%
Tetragon Partners UK LLP	Hedge Fund	2026/Q3	+400,000	0.3%
Renaissance Technologies Corp.	Hedge Fund	2026/Q3	+314,900	0.6%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

Date	Insider	Title	Transaction	Shares	Price	Held after
31 Jul 2026	Roland Kolbeck	Chief Scientific Officer	Derivative Exercise and Sale	-12,385	$5.20	23,990
31 Jul 2026	Roland Kolbeck	Chief Scientific Officer	Derivative Exercise and Retained	+23,990	–	23,990
4 Jun 2026	Vincent Milano	Independent Director	Derivative Exercise and Retained	+11,580	–	28,896
4 Jun 2026	Andrew Schiff	Independent Director	Derivative Exercise and Retained	+11,580	–	25,540
4 Jun 2026	Maxine Gowen	Independent Director	Derivative Exercise and Retained	+11,580	–	33,334
4 Jun 2026	William Humphries	Independent Director	Derivative Exercise and Retained	+11,580	–	45,105
4 Jun 2026	Anand Mehra	Independent Director	Derivative Exercise and Retained	+11,580	–	726,403
4 Jun 2026	Christopher Molineaux	Lead Independent Director	Derivative Exercise and Retained	+11,580	–	69,536
3 Jun 2026	Vincent Milano	Independent Director	Other Derivative Acquisition	+10,987	–	10,987
3 Jun 2026	Vincent Milano	Independent Director	Other Derivative Acquisition	+42,350	$4.71	42,350
3 Jun 2026	Andrew Schiff	Independent Director	Other Derivative Acquisition	+10,987	–	10,987
3 Jun 2026	Andrew Schiff	Independent Director	Other Derivative Acquisition	+42,350	$4.71	42,350
3 Jun 2026	Maxine Gowen	Independent Director	Other Derivative Acquisition	+10,987	–	10,987
3 Jun 2026	Maxine Gowen	Independent Director	Other Derivative Acquisition	+42,350	$4.71	42,350
3 Jun 2026	William Humphries	Independent Director	Other Derivative Acquisition	+10,987	–	10,987
3 Jun 2026	William Humphries	Independent Director	Other Derivative Acquisition	+42,350	$4.71	42,350
3 Jun 2026	Anand Mehra	Independent Director	Other Derivative Acquisition	+10,987	–	10,987
3 Jun 2026	Anand Mehra	Independent Director	Other Derivative Acquisition	+42,350	$4.71	42,350
3 Jun 2026	Christopher Molineaux	Lead Independent Director	Other Derivative Acquisition	+10,987	–	10,987
3 Jun 2026	Christopher Molineaux	Lead Independent Director	Other Derivative Acquisition	+42,350	$4.71	42,350

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report date	Shares short	% of float	Days to cover
15 Sep 2026	16,075,295	10.9%	6.4
31 Aug 2026	15,180,778	10.3%	8.7
14 Aug 2026	14,710,712	10.0%	7.0
31 Jul 2026	13,774,975	9.9%	8.7
15 Jul 2026	13,357,058	9.6%	6.9
30 Jun 2026	11,404,860	8.2%	4.3

Discussion

No comments yet — be the first to weigh in on ACRS.